Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.

Oncology reports - 1 Nov 2020

Montaldi Ana P, Lima Sarah C G, Godoy Paulo R D V, Xavier Danilo J, Sakamoto-Hojo Elza T

Abstract excerpt

Information on the mechanisms that are associated with tumor resistance has the potential to provide the fundamental basis for novel therapeutic strategies. In glioblastoma (GBM), predictive biomarkers of cellular responses to temozolomide (TMZ) combined with poly‑ADP‑ribose polymerase inhibitor (PARPi) remain largely unidentified. In this context, the influence of MGMT (O6‑methylguanine DNA methyltransferase)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to DNA Modification Methylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Poly (ADP-Ribose) Polymerase-1

Share to PTEN Phosphohydrolase

Share to Quinazolines

Share to Temozolomide

Source

Identifiers

PMID: 32901889
DOI: 10.3892/or.2020.7756

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.PMID 32901889Read ↗

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomideSemantic proximity Read ↗

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?Semantic proximity Read ↗

PARP Inhibitor Counteracts Temozolomide Resistance in Glioblastoma MultiformeSemantic proximity Read ↗

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase InhibitorsSemantic proximity Read ↗

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsSemantic proximity Read ↗

PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.Semantic proximity Read ↗

PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomideSemantic proximity Read ↗

Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on GlioblastomaSemantic proximity Read ↗

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision RepairSemantic proximity Read ↗

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical DevelopmentSemantic proximity Read ↗

Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer DrugsSemantic proximity Read ↗

Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.